Prediction of ROR1 and CAV1 expression from whole-exome sequencing of tumor tissue and plasma cfDNA to infer the efficacy of B013 plus nab-paclitaxel in triple-negative breast cancer
Jiang, M.; Zhang, D.; Hsueh, Y.-C.; Zhao, Y.; Zhao, S.; Zhang, Q.; Huang, M.; Gao, P.; Liu, X.; Liu, Y.; Jin, Q.; Dong, W.; Zhang, J.; Ran, R.; Zhang, R.; Fan, Y.; Xu, J.; Tan, G.; Zhang, C.; Zhang, C.; Niu, G.
Show abstract
Accurate prediction of response to targeted anticancer therapy frequently depends on the expression level of the drug target. However, transcriptomic profiling requires tumor tissue that is often unavailable, and circulating cell-free DNA (cfDNA) sequencing carries no expression information. Here, in an in silico companion study to a trial of ROR1 antibody plus nab-paclitaxel in triple-negative breast cancer (TNBC), we transformed whole-exome sequencing (WES) data into somatic activity profiles of signaling pathways (sAPSPs) using the previously published DAGM framework, and used them together with matched expression data to develop regression model sets predicting ROR1 and CAV1 expression. The model sets were applied to 10 trial participants (4 with tumor tissue WES, 6 with plasma cfDNA WES). Patients were classified as predicted-sensitive only when both ROR1 and CAV1 were predicted to be highly expressed. The prediction matched the observed best response in 9 of 10 patients; all three predicted-sensitive patients achieved a partial response. These exploratory findings support the feasibility of WES-based expression prediction for non-invasive response stratification and warrant prospective validation.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Path2Omics: Enhanced transcriptomic and methylation prediction accuracy from tumor histopathology 93%
- Kinome focused CRISPR-Cas9 screens in African ancestry patient-derived breast cancer organoids identifies essential kinases and synergy of EGFR and FGFR1 inhibition. 92%
- Biomarker-guided treatment strategies for ovarian cancer identified from a heterogeneous panel of patient-derived tumor xenografts 92%
Similar papers in this journal
- Multiplexed RNA-FISH-guided Laser Capture Microdissection RNA Sequencing Improves Breast Cancer Molecular Subtyping, Prognostic Classification, and Predicts Response to Antibody Drug Conjugates 93%
- Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer 93%
- Dissecting tumor cell programs through group biology estimation in clinical single-cell transcriptomics 93%
Similar papers in this journal
- Transcriptional pattern enriched for synaptic signaling is associated with shorter survival of patients with high-grade serous ovarian cancer 91%
- DUX4 is a common driver of immune evasion and immunotherapy failure in metastatic cancers 91%
- Limited inhibition of multiple nodes in a driver network blocks metastasis 91%
Similar papers in this journal
- Heterogeneity in signaling pathway activity within primary and between primary and metastatic breast cancer 93%
- The French Early Breast Cancer Cohort (FRESH): a resource for breast cancer research and evaluations of oncology practices based on the French National Healthcare System Database (SNDS) 93%
- From Black Box to Biological Insight: AttentioFuse Unlocks Multi-Omics Dynamics in Lung Cancer 91%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.